Insulin icodec

Insulin icodec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk. It is currently undergoing Phase 3 trials and expected to be submitted for approval in 2023.[1] It is administered via subcutaneous injection once weekly to help control the blood sugar level of those with diabetes. It has a duration of action that lasts more than eight days (compared to 42 hours of the previous longest-acting insulin analogue insulin degludec), making it a once-weekly basal insulin.[2]

See also

References
  1. https://sciencehub.novonordisk.com/congresses/search-results/ada2020/molecular-and-biological-properties-of-insulin-icodec---a-new-in.html
  2. https://pubmed.ncbi.nlm.nih.gov/33944562/
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.